Abstract
Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Current Cancer Therapy Reviews
Title: Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1
Volume: 8 Issue: 1
Author(s): Cherie H. Dunphy
Affiliation:
Keywords: Myeloid neoplasms, lymphoid neoplasms, PDGFRA, PDGFRB, FGFR1
Abstract: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1 result from formation of a fusion gene encoding an aberrant tyrosine kinase. The cell of origin in those neoplasms associated with abnormalities of PDGFRA or FGFR1 is a mutated pluripotent (i.e., myeloid-lymphoid) stem cell, and thus the development of myeloid and lymphoid neoplasms associated with these abnormalities. Reported neoplasms associated with abnormalities of PDGFRB have been only myeloid in origin. This review presents the definitions and characteristic cytomorphological, immunophenotypic, cytogenetic, and molecular features of these neoplasms and discusses in depth the differential diagnoses. Following this presentation, the review then focuses on therapeutic approaches, including targeted therapy.
Export Options
About this article
Cite this article as:
H. Dunphy Cherie, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462503
DOI https://dx.doi.org/10.2174/157339412799462503 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Importance of Kier-Hall Topological Indices in the QSAR of Anticancer Drug Design
Current Computer-Aided Drug Design Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Methodological Aspects and Applications of In Vivo Imaging of Apoptosis in Oncology: An Illustrative Review
Current Medical Imaging Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Cancer Pharmacogenomics: Germline DNA, Tumor DNA, or Both?
Current Pharmacogenomics Molecular Mechanisms Responsible for <i>In Vitro</i> Cytotoxic Attributes of <i>Conyza bonariensis</i> Extract against Lymphoblastic Leukaemia Jurkat Cells
Anti-Cancer Agents in Medicinal Chemistry Intramolecular Cyclisation of β-Aryl-β-Amino Acids in the Design of Novel Heterocyclic Systems with Therapeutic Interest: An Unfailing Source of Diversity
Current Medicinal Chemistry Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Current Strategies to Target the Anti-Apoptotic Bcl-2 Protein in Cancer Cells
Current Medicinal Chemistry The Role of Glycogen Synthase Kinase-3β in Normal Haematopoiesis, Angiogenesis and Leukaemia
Current Medicinal Chemistry Nontoxic-dose of Deguelin Induce NPMc+ AML Cell Differentiation by Selectively Targeting Mt NPM1/SIRT1 Instead of HDAC1/3
Current Cancer Drug Targets STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Therapeutic Potential of Inhibiting Brutons Tyrosine Kinase, (BTK)
Current Pharmaceutical Design Pluripotent Stem Cells for Livestock Health and Production
Current Stem Cell Research & Therapy Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Meet Our Editorial Board Member
Current Organic Synthesis Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design